| Index | S&P 500 | P/E | 72.19 | EPS (ttm) | 2.10 | Insider Own | 0.50% | Shs Outstand | 111.59M | Perf Week | -5.48% |
| Market Cap | 16.92B | Forward P/E | 25.71 | EPS next Y | 5.90 | Insider Trans | -1.63% | Shs Float | 102.49M | Perf Month | 0.05% |
| Enterprise Value | 19.23B | PEG | 7.55 | EPS next Q | 1.30 | Short Float | 6.24% | Perf Quarter | 36.10% | ||
| Income | 238.00M | P/S | 5.81 | EPS this Y | 8.52% | Short Ratio | 3.46 | Perf Half Y | 75.24% | ||
| Sales | 2.91B | P/B | 2.34 | EPS next Y | 10.06% | ROA | 1.97% | Short Interest | 6.39M | Perf YTD | 56.69% |
| Book/sh | 64.78 | P/C | 16.54 | EPS next 5Y | 9.56% | ROE | 3.27% | 52W High | 169.06 -10.33% | Perf Year | 66.56% |
| Cash/sh | 9.17 | P/FCF | 30.26 | EPS past 3/5Y | -22.69% -20.37% | ROIC | 2.91% | 52W Low | 81.22 86.65% | Perf 3Y | 53.21% |
| Dividend Est. | 0.28 (0.18%) | EV/EBITDA | 25.04 | Sales past 3/5Y | -4.82% -5.47% | Gross Margin | 52.11% | Volatility | 4.31% 4.02% | Perf 5Y | -14.44% |
| Dividend TTM | 0.28 (0.18%) | EV/Sales | 6.61 | EPS Y/Y TTM | -10.96% | Oper. Margin | 12.32% | ATR (14) | 6.26 | Perf 10Y | 187.72% |
| Dividend Ex-Date | Jan 22, 2027 | Quick Ratio | 1.50 | Sales Y/Y TTM | 4.07% | Profit Margin | 8.16% | RSI (14) | 47.37 | Recom | 2.48 |
| Dividend Gr. 3/5Y | 0.00% 0.00% | Current Ratio | 1.80 | EPS Q/Q | 19.49% | SMA20 | -2.98% | Beta | 1.07 | Target Price | 132.13 |
| Payout | 13.36% | Debt/Eq | 0.46 | Sales Q/Q | 1.39% | SMA50 | 4.54% | Rel Volume | 1.51 | Prev Close | 157.00 |
| Employees | 11,000 | LT Debt/Eq | 0.38 | Earnings | Nov 03 | SMA200 | 35.28% | Avg Volume | 1.85M | Price | 151.60 |
| IPO Date | Jul 06, 1965 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 16.16% 1.14% | Net Debt/EBITDA | 3.02 | Volume | 2,798,210 | Change | -3.44% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-07-26 | Reiterated | Barclays | Equal Weight | $95 → $160 |
| Sep-09-26 | Reiterated | UBS | Buy | $120 → $140 |
| Sep-04-26 | Reiterated | Keybanc | Overweight | $132 → $165 |
| Sep-01-26 | Reiterated | RBC Capital | $135 | |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $118 → $125 |
| Jun-26-26 | Resumed | Bernstein | Market Perform | $130 → $115 |
| May-06-26 | Reiterated | Stifel Nicolaus | $110 → $100 | |
| May-06-26 | Reiterated | Robert W. Baird | $125 → $117 | |
| May-04-26 | Reiterated | Robert W. Baird | $129 → $125 | |
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight | $118 → $95 |
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/28/2025 | FY 2024 12/29/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,912 | 2,856 | 2,755 | 2,751 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,394 | 1,340 | 1,432 | 1,428 | — | — | — | — | — | |
| Gross Profit | 1,518 | 1,516 | 1,323 | 1,322 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 943 | 945 | 715 | 706 | — | — | — | — | — | |
| Research and Development | 216 | 216 | 197 | 217 | — | — | — | — | — | |
| Other Operating Expense | 0 | -2 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 359 | 357 | 411 | 399 | — | — | — | — | — | |
| Interest Expense | 95 | 92 | 96 | 99 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -4 | 4 | 2 | -118 | — | — | — | — | — | |
| Net Income Before Taxes | 262 | 268 | 316 | 183 | — | — | — | — | — | |
| Income Taxes | 20 | 26 | 33 | 3 | — | — | — | — | — | |
| Consolidated Net Income | 238 | 242 | 296 | -118 | — | — | — | — | — | |
| Net Income From Continuing Operations | 239 | 242 | 283 | 180 | — | — | — | — | — | |
| Net Income | 238 | 242 | 296 | -118 | — | — | — | — | — | |
| EPS (Recurring) | 2.10 | 2.08 | 2.41 | -0.95 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.10 | 2.08 | 2.41 | -0.95 | — | — | — | — | — | |
| EPS (Diluted) | 2.10 | 2.08 | 2.41 | -0.95 | — | — | — | — | — | |
| EBITDA | 768 | 766 | 840 | 714 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 72.19 | 46.51 | 46.47 | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.83 | 3.83 | 5.00 | 4.97 | — | — | — | — | — | |
| Gross Margin | 52.13 | 53.08 | 48.02 | 48.06 | — | — | — | — | — | |
| Operating Margin | 12.33 | 12.50 | 14.92 | 14.50 | — | — | — | — | — | |
| Net Margin | 8.17 | 8.47 | 10.74 | -4.29 | — | — | — | — | — | |
| Shares Outstanding | 112 | 113 | 123 | 125 | — | — | — | — | — | |
| Market Capitalization | 16,979 | 10,933 | 13,775 | 13,664 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gonzales Anita | VP and CAO | Oct 01 '26 | Sale | 155.48 | 84 | 13,060 | 7,117 | Oct 02 |
| Krakowiak Maxwell | Please See Remarks | Sep 21 '26 | Sale | 144.53 | 1,631 | 235,728 | 14,781 | Sep 23 |
| Vohra Tajinder S | Please See Remarks | Sep 16 '26 | Sale | 140.88 | 7,330 | 1,032,650 | 6,635 | Sep 18 |
| Gonzales Anita | Vice President and CAO | Jul 20 '26 | Sale | 109.48 | 85 | 9,306 | 7,201 | Jul 22 |
| Gonzales Anita | Vice President and CAO | Apr 20 '26 | Sale | 92.80 | 80 | 7,424 | 7,319 | Apr 22 |
| Victor Miriame | Please See Remarks | Feb 24 '26 | Option Exercise | 95.74 | 3,724 | 356,536 | 19,984 | Feb 26 |
| Victor Miriame | Please See Remarks | Feb 24 '26 | Sale | 97.13 | 1,862 | 180,856 | 18,122 | Feb 26 |
| McMurry-Heath Michelle | Director | Feb 23 '26 | Sale | 97.26 | 600 | 58,356 | 4,233 | Feb 25 |
| Singh Prahlad R. | Please See Remarks | Feb 05 '26 | Sale | 100.21 | 25,525 | 2,557,859 | 120,213 | Feb 06 |
| Singh Prahlad R. | Please See Remarks | Feb 05 '26 | Option Exercise | 92.09 | 25,525 | 2,350,597 | 145,738 | Feb 06 |
| Goldberg Joel S | Please See Remarks | Feb 05 '26 | Option Exercise | 92.09 | 12,717 | 1,171,109 | 55,964 | Feb 06 |
| Goldberg Joel S | Please See Remarks | Feb 05 '26 | Sale | 100.21 | 12,717 | 1,274,357 | 43,247 | Feb 06 |
| Vohra Tajinder S | Please See Remarks | Feb 02 '26 | Option Exercise | 92.09 | 11,512 | 1,060,140 | 16,198 | Feb 04 |
| Vohra Tajinder S | Please See Remarks | Feb 02 '26 | Sale | 104.50 | 5,756 | 601,502 | 10,442 | Feb 04 |
| MICHAS ALEXIS P | Director | Aug 27 '25 | Sale | 89.01 | 500 | 44,505 | 7,270 | Aug 28 |